Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.12.28.21268472: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: A p-value < 0.05 was considered statistically significant The study was approved by the Institutional Ethics Committee, Maulana
Consent: Electronic and informed consent was obtained from all the study participants.Sex as a biological variable not detected. Randomization The samples for screening were selected through computer-based simple random sampling method. Blinding not detected. Power Analysis This sample size was adequate at 95% confidence levels with 1.2% absolute precision levels. Table 2: Resources
Antibodies Sentences Resources The sVNT kit detects circulating neutralizing anti SARS-CoV-2 antibodies through immune system response either after COVID-19 infection or vaccination. anti …SciScore for 10.1101/2021.12.28.21268472: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: A p-value < 0.05 was considered statistically significant The study was approved by the Institutional Ethics Committee, Maulana
Consent: Electronic and informed consent was obtained from all the study participants.Sex as a biological variable not detected. Randomization The samples for screening were selected through computer-based simple random sampling method. Blinding not detected. Power Analysis This sample size was adequate at 95% confidence levels with 1.2% absolute precision levels. Table 2: Resources
Antibodies Sentences Resources The sVNT kit detects circulating neutralizing anti SARS-CoV-2 antibodies through immune system response either after COVID-19 infection or vaccination. anti SARS-CoV-2suggested: NoneThese antibodies prevent the interaction between the ACE2 human cell surface receptor and the receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein [ SARS-CoV-2 spike glycoprotein [suggested: NoneSoftware and Algorithms Sentences Resources Data were analysed with IBM SPSS Statistics for Windows, Version 25.0. SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
